Myles tweet18 Aug 2021 18:46
I very much like this taken from page 9 of the report:
Calibre Scientific is, at the time of writing (we checked this morning), out of stock of Avacta’s AffiDX SARS- CoV-2 LFT. In fact, it was sold out before it even received first shipment of the product. It stands to reason, therefore, that Avacta will indeed be bringing online its international manufacturing contractor (capacity of up to a further 30 million per month) as soon as possible. To reiterate: management has stated that gross profit per LFT sold will be in the region of €1 to €2. Its implied target output of 35 million per month (5 million in the UK; 30 million abroad) would therefore suggest £420m gross profit per year. We assume £20m Group cash burn for CY 2022, excluding AffiDX LFT activities